Caroline's Feed
Aug 8, 2013

Adecco sees European labor markets at turning point

ZURICH (Reuters) – European labor markets have reached a turning point, world No. 1 staffing firm Adecco (ADEN.VX: Quote, Profile, Research, Stock Buzz) said on Thursday, as it beat second-quarter profit expectations and saw its shares surge to a two-and-a-half year high.

Staffing firms are regarded by analysts as good indicators of future economic trends and Adecco’s more optimistic tone about the euro zone could add to expectations it will move out of recession later this year.

Aug 7, 2013

Venture capital warms to European biotechs

ZURICH (Reuters) – While a wave of stock market enthusiasm in the United States for biotech company flotations has yet to cross the Atlantic, venture capital appetite for promising European companies is returning.

Biotech is hot on Wall Street, with the Nasdaq sector index up 43 percent this year, listed U.S. stocks scaling all-time highs and roughly 23 biotech companies going public.

Jul 25, 2013

Roche tops forecast as new cancer drugs gain momentum

BASEL, Switzerland, July 25 (Reuters) – Swiss
pharmaceuticals firm Roche beat first-half profit
forecasts as strong sales of its mainstay cancer drugs and some
new treatments supported its view that it can withstand
competition from cheap, copycat drugmakers.

The results also stoked speculation the group might hike its
dividend, buy back shares and make more acquisitions as it looks
to diversify from its core expertise in cancer.

Jul 24, 2013

Cold, wet spring weighs on Syngenta first-half results

ZURICH, July 24 (Reuters) – Syngenta AG, the
world’s largest maker of crop chemicals, said on Wednesday it
expected underlying sales growth to pick up pace in the second
half of the year, after a cold, wet spring hit earnings in the
first six months.

Syngenta said it was confident high commodity prices would
encourage farmers to invest in crops in the second half of the
year, when demand is driven by South American farmers, and help
its 2013 sales surpass last year’s record of $14.2 billion.

Jul 23, 2013

Swatch expects Chinese to buy more Omega watches

ZURICH (Reuters) – The world’s biggest watchmaker, Swatch Group (UHR.VX: Quote, Profile, Research, Stock Buzz), said it expects faster sales growth and better margins in the second half as its Omega brand is growing again in China while demand for Harry Winston jewellery is buoyant.

In the first half of the year, there have been double-digit percentage falls in Swiss watch exports to China and Hong Kong, which absorbed a quarter of the timepieces that left Switzerland between January and June.

Jul 22, 2013

Roche takes its hunt for a new chairman further afield

ZURICH, July 22 (Reuters) – Swiss drugmaker Roche
faces the prospect of hiring an outsider to replace its chairman
of 16 years after its most suitable board members turned down
the job.

The 117-year old company – the world’s largest maker of
cancer drugs – set itself an autumn deadline to find a successor
to Franz Humer, an influential, hands-on former Roche chief
executive who says he will not stand for re-election next year.

Jul 18, 2013

Actelion raises profit forecast as cost cuts kick in

ZURICH, July 18 (Reuters) – Actelion, the Swiss
drugmaker which relies on sales of its treatment for a rare lung
disease, raised its full-year profit forecast on Thursday on
cost-savings and better-than-expected sales of its mainstay
product.

Europe’s largest biotech company said it expected core
earnings to cross into the double-digit percentage range for
2013, up from a previous guidance of stable core earnings, after
cost savings kicked in quicker than expected.

Jul 17, 2013

Novartis lifts full-year outlook after competition delay

ZURICH, July 17 (Reuters) – Novartis raised its
full-year outlook on Wednesday after generic competition to its
best-selling blood pressure pill was delayed, granting the Swiss
drugmaker a temporary reprieve from patent losses.

The Basel-based firm lost its patent rights on Diovan in the
United States last year and faced competition from a copycat
version of its monotherapy from Ranbaxy Laboratories.
But the lab has so far failed to get a green light for
production from U.S. regulators.

Jul 14, 2013

Alexion valuation could choke any Roche bid

ZURICH (Reuters) – Buying Alexion Pharmaceuticals Inc (ALXN.O: Quote, Profile, Research, Stock Buzz) would help Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drug maker is ultimately not willing to pay.

Two people familiar with the matter have told Reuters that the Basel-based firm is seeking financing for a potential bid for Alexion, which specializes in the treatment of rare diseases.

Jul 8, 2013

Europe floods to cost insurers up to $4.5 billion -Swiss Re

ZURICH, July 8 (Reuters) – Floods in central Europe last
month may cost insurance companies $3.5-4.5 billion, only half
of one previous estimate but more than was paid out for the last
major washout in 2002, the world’s second biggest reinsurer said
on Monday.

The forecast from Swiss Re compares to an earlier
warning from a damage modelling agency that losses could top $8
billion. That, and its estimate of a $300 million hit for its
own results, saw shares in Swiss Re and some other sector firms
rise.